# NOV 1 8 2005

Ms. Carol Ruggiero Director of Regulatory Affairs Cliniqa Corporation 1432 South Mission Road Fallbrook, CA 92028

Re: k052679 Trade/Device Name: CLINIQA Liquid QCTM Bilirubin Controls Levels 1, 2 & 3 CLINIQA LiniCAL TM Bilirubin Calibration Verifiers Levels A-E for Olympus AU SystemsTM Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJX Dated: September 26, 2005 Received: September 28, 2005

Dear Ms. Ruggiero:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that avebee reclassi  rdance with he provisons  he Fedral FoodDrg and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device s classified (se above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/0d03a45f31731895d9cb5e8b9caaffac24d8661ec1ba599315096622818949f6.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

510(k) Number (if known): 52679

# Device Name: CLINIQA Liquid $\mathsf { Q C } ^ { \mathsf { T M } }$ Bilirubin Controls Levels 1, 2 & 3

Indications For Use:   
CLINIQA Liquid QC™ Bilirubin Controls Levels 1, 2 & 3 are intended for use as an assayed quality control material. Three assayed levels of Total and Direct Bilirubin are provided.

Device Name: CLINIQA LiniCAL ™ Bilirubin Calibration Verifiers Levels A - E for Olympus AU Systems ™ .

Indications For Use:

CLINIQA LiniCAL ™ Bilirubin Calibration Verifiers Levels A - E for Olympus AU Systems™ are assayed, liquid, quality control products which may be used to evaluate the performance of the Olympus AU Systems ™ for Total and Direct Bilirubin at five useful concentrations.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE FNEEDED)

Concurrence of CDRH, Pffice of In Vitro Diagnostic Devices (OIVD) ay pllp Office of In Vitro Diagnostic Device Evaluatlon and Safety 510K K052679